Pharmacogenomics and Active Surveillance for Serious Adverse Drug Reactions in Children

• Moore TJ , PsatyBM, FurbergCD: Time to act on drug safety.JAMA279(19) , 1571–1573 (1998).
   PubMed Web of Science ®Google Scholar
• Davies EC , GreenCF, TaylorS, WilliamsonPR, MottramDR, PirmohamedM: Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes.PLoS One4(2) , E4439 (2009).
   PubMed Web of Science ®Google Scholar
• Hazell L , ShakirSA: Under-reporting of adverse drug reactions: a systematic review.Drug Saf.29(5) , 385–396 (2006).
   PubMed Web of Science ®Google Scholar
• WHO: International Drug Monitoring: The Role of the Hospital. Geneva, Switzerland: WHO. Technical Report Series No. 425, 5–24 (1969).
   Google Scholar
• Sibbald B : Rofecoxib (Vioxx) voluntarily withdrawn from market.CMAJ171(9) , 1027–1028 (2004).
   PubMed Web of Science ®Google Scholar
• Amit D , RataboliPV: Adverse drug reaction (ADR) notification drop box: an easy way to report ADRs.Br. J. Clin. Pharmacol.66(5) , 723–724 (2008).
   PubMed Web of Science ®Google Scholar
• Lazarou J , PomeranzBH, CoreyPN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA279(15) , 1200–1205 (1998).
   PubMed Web of Science ®Google Scholar
• Pirmohamed M , JamesS, MeakinS et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.BMJ329(7456) , 15–19 (2004).
   PubMed Web of Science ®Google Scholar
• Brvar M , FokterN, BuncM, MozinaM: The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty.BMC Clin. Pharmacol.9 , 8 (2009).
   PubMedGoogle Scholar
• Winterstein AG , SauerBC, HeplerCD, PooleC: Preventable drug-related hospital admissions.Ann. Pharmacother.36(7–8) , 1238–1248 (2002).
   PubMed Web of Science ®Google Scholar
• Eichelbaum M , Ingelman-SundbergM, EvansWE: Pharmacogenomics and individualized drug therapy.Annu. Rev. Med.57 , 119–137 (2006).
   PubMed Web of Science ®Google Scholar
• White TJ , ArakelianA, RhoJP: Counting the costs of drug-related adverse events.Pharmacoeconomics15(5) , 445–458 (1999).
   PubMed Web of Science ®Google Scholar
• Phillips KA , VeenstraD, van Bebber S, Sakowski J: An introduction to cost–effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics4(3) , 231–239 (2003).
   PubMed Web of Science ®Google Scholar
• Ernst FR , GrizzleAJ: Drug-related morbidity and mortality: updating the cost-of-illness model.J. Am. Pharm. Assoc. (Wash)41(2) , 192–199 (2001).
   PubMedGoogle Scholar
• Leeder JS : Developmental and pediatric pharmacogenomics.Pharmacogenomics4(3) , 331–341 (2003).
   PubMed Web of Science ®Google Scholar
• Stephenson T : How children‘s responses to drugs differ from adults.Br. J. Clin. Pharmacol.59(6) , 670–673 (2005).
   PubMed Web of Science ®Google Scholar
• Wong I , SweisD, CopeJ, FlorenceA: Paediatric medicines research in the UK: how to move forward?Drug Saf.26(8) , 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• Neubert A , DormannH, WeissJ et al.: The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.Drug Saf.27(13) , 1059–1067 (2004).
   PubMed Web of Science ®Google Scholar
• Maitland ML , VasishtK, RatainMJ: TPMT, UGT1A1 and DPYD : genotyping to ensure safer cancer therapy?Trends Pharmacol. Sci.27(8) , 432–437 (2006).
   PubMed Web of Science ®Google Scholar
• Kearns GL , Abdel-RahmanSM, AlanderSW, BloweyDL, LeederSJ, KauffmanRE: Developmental pharmacology-drug disposition, action, and therapy in infants and children.N. Engl. J. Med.349(12) , 1157–1167 (2003).
   PubMed Web of Science ®Google Scholar
• Strassburg CP , StrassburgA, KneipS et al.: Developmental aspects of human hepatic drug glucuronidation in young children and adults.Gut50(2) , 259–265 (2002).
   PubMed Web of Science ®Google Scholar
• Omari AA , MurryDJ: Pharmacogenetics of the cytochrome P450 enzyme system: review of current knowledge and clinical significance.J. Pharm. Pract.20(3) , 206–218 (2007).
   Google Scholar
• Lacroix D , SonnierM, MoncionA, CheronG, CresteilT: Expression of CYP3A in the human liver – evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.Eur. J. Biochem247(2) , 625–634 (1997).
   PubMedGoogle Scholar
• Cresteil T : Onset of xenobiotic metabolism in children: toxicological implications.Food Addit. Contam.15(Suppl.) 45–51 (1998).
   PubMed Web of Science ®Google Scholar
• Carleton B , PooleR, SmithM et al.: Adverse drug reaction active surveillance: developing a national network in Canada‘s children‘s hospitals.Pharmacoepidemiol. Drug Saf.18(8) , 713–721 (2009).
   PubMed Web of Science ®Google Scholar
• Impicciatore P , ChoonaraI, ClarksonA, ProvasiD, PandolfiniC, BonatiM: Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies.Br. J. Clin. Pharmacol.52(1) , 77–83 (2001).
   PubMed Web of Science ®Google Scholar
• Kongkaew C , NoycePR, AshcroftDM: Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies.Ann. Pharmacother.42(7) , 1017–1025 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson MR , BacanuSA, MostellerM et al.: Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.Pharmacogenomics J.9(1) , 23–33 (2009).
   PubMed Web of Science ®Google Scholar
• Li Y , WomerRB, SilberJH: Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.Eur. J. Cancer40(16) , 2445–2451 (2004).
   PubMed Web of Science ®Google Scholar
• Coradini PP , CiganaL, SelistreSG, RositoLS, BrunettoAL: Ototoxicity from cisplatin therapy in childhood cancer.J. Pediatr. Hematol. Oncol.29(6) , 355–360 (2007).
   PubMed Web of Science ®Google Scholar
• Knight KR , KraemerDF, NeuweltEA: Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.J. Clin. Oncol.23(34) , 8588–8596 (2005).
   PubMed Web of Science ®Google Scholar
• Kushner BH , BudnickA, KramerK, ModakS, CheungNK: Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.Cancer107(2) , 417–422 (2006).
   PubMed Web of Science ®Google Scholar
• Ross CJ , Katzov-EckertH, DubeMP et al.: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.Nat. Genet.41(12) , 1345–1349 (2009).
   PubMed Web of Science ®Google Scholar
• Oldenburg J , KraggerudSM, CvancarovaM, LotheRA, FossaSD: Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors.J. Clin. Oncol.25(6) , 708–714 (2007).
   PubMed Web of Science ®Google Scholar
• Peters U , Preisler-AdamsS, HebeisenA et al.: Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.Anticancer Drugs11(8) , 639–643 (2000).
   PubMed Web of Science ®Google Scholar
• Riedemann L , LanversC, DeusterD et al.: Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.Pharmacogenomics J.8(1) , 23–28 (2008).
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM : Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.Cell. Mol. Neurobiol.26(4–6) , 539–561 (2006).
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM , SladekSL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.Am. J. Hum. Genet.32(5) , 651–662 (1980).
   PubMed Web of Science ®Google Scholar
• Ochoa B , BobadillaN, ArrellinG, HerreraLA: S-Adenosyl-l-methionine increases serum BUN and creatinine in cisplatin-treated mice.Arch. Med. Res.40(1) , 54–58 (2009).
   PubMed Web of Science ®Google Scholar
• Koren G , CairnsJ, ChitayatD, GaedigkA, LeederSJ: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.Lancet372(9639) , 625–626 (2008).
   PubMedGoogle Scholar
• Jin C , MinersJO, LillywhiteKJ, MackenziePI: Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs.J. Pharmacol. Exp. Ther.264(1) , 475–479 (1993).
   PubMed Web of Science ®Google Scholar
• Madadi P , RossCJ, HaydenMR et al.: Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.Clin. Pharmacol. Ther.85(1) , 31–35 (2009).
   PubMed Web of Science ®Google Scholar
• Sawyer MB , InnocentiF, DasS et al.: A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.Clin. Pharmacol. Ther.73(6) , 566–574 (2003).
   PubMed Web of Science ®Google Scholar
• Choonara IA , McKayP, HainR, RaneA: Morphine metabolism in children.Br. J. Clin. Pharmacol.28(5) , 599–604 (1989).
   PubMed Web of Science ®Google Scholar
• Blake MJ , GaedigkA, PearceRE et al.: Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.Clin. Pharmacol. Ther.81(4) , 510–516 (2007).
   PubMed Web of Science ®Google Scholar
• Willmann S EA, Coboeken K, Ahr G, Lippert J: Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin. Pharmacol. Ther.86(6) , 634–643(2009).
   PubMed Web of Science ®Google Scholar
• Peter EA , JanssenPA, GrangeCS, DouglasMJ: Ibuprofen versus acetaminophen with codeine for the relief of perineal pain after childbirth: a randomized controlled trial.CMAJ165(9) , 1203–1209 (2001).
   PubMed Web of Science ®Google Scholar
• Transfer of drugs and other chemicals into human milk. Pediatrics108(3) , 776–789 (2001).
   PubMed Web of Science ®Google Scholar
• Briggs GG , FreemanRK, YaffeSJ: Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (7th edition). Lippincott Williams Wilkins, PA, USA. (2005).
   Google Scholar
• Briggs GG , FreemanRK, YaffeSJ: Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (8th edition). Lippincott Williams Wilkins, PA, USA. 421–422 (2008).
   Google Scholar
• Madadi P MM, Djokanovic N, Bozzo P, Nulman I, Ito S, Koren G: Guidelines for maternal codeine use during breastfeeding. Can. Fam. Physician55(11) , 1077–1078 (2009).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M : Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.N. Engl. J. Med.358(6) , 637–639 (2008).
   PubMed Web of Science ®Google Scholar
• Mallal S , PhillipsE, CarosiG et al.: HLA-B*5701 screening for hypersensitivity to abacavir.N. Engl. J. Med.358(6) , 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Zucman D , TruchisP, MajerholcC, StegmanS, Caillat-ZucmanS: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population.J. Acquir. Immune Defic. Syndr.45(1) , 1–3 (2007).
   PubMed Web of Science ®Google Scholar
• Davidsen ML , DalhoffK, SchmiegelowK: Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.J. Pediatr. Hematol. Oncol.30(11) , 831–849 (2008).
   PubMed Web of Science ®Google Scholar
• Ikediobi ON , ShinJ, NussbaumRL et al.: Addressing the challenges of the clinical application of pharmacogenetic testing.Clin. Pharmacol. Ther.86(1) , 28–31 (2009).
   PubMed Web of Science ®Google Scholar

▪ Websites

• United States Government Accountability Office (GAO): Drug Safety: Improvements Needed in FDA‘s Postmarket Decision-making and Oversight Process. Publication GAO-06-402 (2006) www.gao.gov/new.items/d06402.pdf (Accessed 26August2010)
   Google Scholar
• Merck announces voluntary worldwide withdrawal of Vioxx. Merck & Co. Press Release2001 www.vioxx.com/vioxx/documents/english/vioxx_press_release.pdf (Accessed 4January2010)
   Google Scholar
• Office of the Inspector General, Department of Human and Health Services. Review of Food and Drug Administration‘s Handling of Adverse Drug Reaction Reports. Report No.: A-15-98-50001 (1999) http://oig.hhs.gov/oas/reports/phs/c9850001.pdf (Accessed 26August2010)
   Google Scholar
• Patterns of medication use in the USA: a report from the Slone survey. Slone Epidemiology Center.2006 www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdf (Accessed 26August2010)
   Google Scholar
• Expiry of the Interim Order that permitted the sale of oseltamivir (Tamiflu®) for use in children under one year of age in the context of Pandemic H1N1 2009 www.phac-aspc.gc.ca/alert-alerte/h1n1/guidance_lignesdirectrices/guidance-tamiflu-eng.php (Accessed 26August2010)
   Google Scholar
• National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children http://clinicaltrials.gov/ct2/show/NCT00414115 (Accessed 26August2010)
   Google Scholar
• Secretary‘s Advisory Committee on Genetics, Health, and Society, Department of Health and Human Services: Realizing the Potential of Pharmacogenomics: Opportunities and Challenges. Office of Science Policy, National Institute of Health (2008) http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_PGx_report.pdf (Accessed 26August2010)
   Google Scholar
• Statistics Canada. CANISM database. Table 105–0244. http://cansim2.statcan.ca (Accessed 26August2010)
   Google Scholar
• Canadian Institute for Health Information. Giving Birth in Canada: Providers of Maternity and Infant Care http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=PG_262_E&cw_topic=262&cw_rel=AR_1106_E (Accessed 26August2010)
   Google Scholar
• US FDA: Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (Accessed 4January2010)
   Google Scholar
• EGAPP: Evaluation of Genomic Applications in Practice and Prevention. EGAPP Working Group Recommendations www.egappreviews.org/recommendations/index.htm (Accessed 1June2010)
   Google Scholar